Disparities in GBM treatment: Demand More!
Survey shows huge disparities in treatment.
UK ranks 22nd out of 29 comparable countries for survival of Brain Cancer
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
Experimental GBM treatment — DC Vax — is hoped to be moving forward in the UK
NW Biotherapeutics, maker of DC Vax to treat glioblastoma — applied for approval in the UK.
White House Cancer Moonshot
OurBrainBank is proud that the White House invited us to be part of the ambitious Cancer Moonshot effort. Read the latest from Washington DC.